WilmerHale Advises Millennium Pharmaceuticals in $8.8 Billion Acquisition by Takeda

WilmerHale Advises Millennium Pharmaceuticals in $8.8 Billion Acquisition by Takeda

Firm News

Related Solutions

With a team of lawyers recognized nationally as leading practitioners in the field, we regularly advise public and private companies, their shareholders and their key employees on tax aspects of mergers, acquisitions, dispositions and joint ventures. Clients rely on our advice to maximize their tax efficiencies and minimize their tax risks. Our clients include businesses from a wide range of sectors: technology, life sciences, publishing, telecommunications, aviation and defense, venture capital and private equity. We develop tax-efficient structures that help clients achieve business objectives and negotiate appropriate contractual protections against the assumption of unwanted tax risks.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.
Handling complex antitrust and competition litigation across the US, UK and Europe, representing both plaintiffs and defendants in various high-stakes cases.
A global team handling highly complex and sensitive matters in all aspects of litigation.
We offer clients exceptional insight in dealing with competition agencies in the United States, Europe and around the world.
A team of WilmerHale lawyers advised Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) in connection with its proposed $8.8 billion acquisition by Takeda Pharmaceutical Company Limited (TSE: 4502) through a cash tender offer. The deal is the largest overseas acquisition by a Japanese drug manufacturer.

Serving as Millennium’s M&A counsel in the transaction are WilmerHale lawyers David Redlick, Hal Leibowitz, Jeffrey Hermanson, Brian Johnson, Emily Babalas, Jason Kropp and Sonia Bednarowski. The M&A team is assisted by antitrust partners William Kolasky and Sven Voeckler, and tax partners William Schmidt and Robert Burke.

WilmerHale has served as primary outside counsel to Millennium since the early 1990s. Millennium is a leading biopharmaceutical company based in Cambridge, Massachusetts that markets VELCADE, a novel cancer product, and has oncology and inflammation product candidates in various stages of development.

Click here for Millennium Pharmaceutical’s complete press release.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel